BARDA

AVITA Medical Reports Fourth Quarter and Fiscal Year 2021 Financial Results

Retrieved on: 
Thursday, August 26, 2021
Industry, Company, AVH, Contraindication, BARDA, Health care, COVID, Epidermis, Burn, Growth, Office of the Assistant Secretary for Preparedness and Response, USE, Avita, Burns, Skin, Regenerative medicine, GLOBE, Total, Avita Medical, Research, Travel, Food, Assistant, Marketing, Forward-looking statement, Autotransplantation, Clinical trial, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Development, NASDAQ, Safety, Adult, ASX, Failure, Acceleration, Patient, Solution, FDA, COVID-19, Vitiligo, Technology, Regulation of tobacco by the U.S. Food and Drug Administration, Biomedical Advanced Research and Development Authority, Fossil fuel, Pharmaceutical industry

VALENCIA, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today reported financial results for its fourth quarter of fiscal year 2021, ended June 30, 2021.

Key Points: 
  • VALENCIA, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today reported financial results for its fourth quarter of fiscal year 2021, ended June 30, 2021.
  • Total net revenue increased 166% to $10.3 million, compared to $3.9 million in the corresponding period in the prior year.
  • The Company will host a conference call to discuss the fourth quarter financial results after market close on Thursday, August 26, 2021, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time (being 6.30 a.m. Australian Eastern Standard Time on Friday, August 27, 2021).
  • Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
    AVITA Medical, Inc. is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications.

Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Evaluated in NIH-Sponsored Phase 3 Clinical Trial (INSIGHT-012) of Hyperimmune Intravenous Immunoglobulin for Outpatient Treatment of COVID-19

Retrieved on: 
Wednesday, August 25, 2021
BARDA, Private Securities Litigation Reform Act, Coronavirus, Twitter, COVID, Biomedical Advanced Research and Development Authority, Instagram, Therapy, Severe acute respiratory syndrome coronavirus 2, Life, GLOBE, SEC, Disease, Assistant, Social responsibility, SVP, Death, Marketing, Emergent BioSolutions, Antibody, National, National Institute of Allergy and Infectious Diseases, Immunodeficiency, NYSE, Risk, Public health, Development, Safety, Adult, Patient, EBS, Solution, LinkedIn, Vaccine, Infection, Emergent, NIH, Plasma, FDA, COVID-19, Department, National Institute, Pharmaceutical industry

The INSIGHT-012 clinical study called Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

Key Points: 
  • The INSIGHT-012 clinical study called Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
  • Treatment with COVID-HIG earlier in the COVID-19 disease course offers a window of intervention when viral replication is extensive but natural antibody response hasnt been generated yet.
  • This earlier intervention has the potential to improve patient outcomes and keep people out of the hospital.
  • Emergent is one of two companies providing hyperimmune globulin products for the trial, which plans to enroll approximately 800 patients across U.S. and international clinical trial sites.

CHO Plus Announces Acceptance Into BLUE KNIGHT™

Retrieved on: 
Tuesday, August 24, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious Diseases, Genetics, Johnson & Johnson, BARDA, Investor, Disease, Biomedical Advanced Research and Development Authority, Virus, Cancer, The Blue Knight, Pandemic, Health, Golgi apparatus, CA, Antibody, Cell, Development, Endoplasmic reticulum, Vaccine, CEO, Technology, Fine chemical

Blue Knight is a joint initiative created between Johnson & Johnson Innovation and the Biomedical Advanced Research and Development Authority (BARDA).

Key Points: 
  • Blue Knight is a joint initiative created between Johnson & Johnson Innovation and the Biomedical Advanced Research and Development Authority (BARDA).
  • CHO Plus technology could expand the existing manufacturing capacity for production of therapeutic proteins and vaccines thus making the company a good fit for the mission of the Blue Knight program.
  • Through dedicated mentorship, CHO Plus will work with BARDA representatives and associates toward mutually beneficial goals.
  • James Panek, CHO Plus COO, added: We are grateful for the confidence the Blue Knight initiative has shown in our technology, and for the financial support.

Velico Medical achieves two significant milestones in developing spray dried plasma for lifesaving point-of-care transfusions

Retrieved on: 
Tuesday, August 24, 2021
BARDA, PMA, Joint Medical Service (Germany), Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response, Human services, Trial of the century, Surgeon, Trauma, Boston MedFlight, Research, Government, Food, Assistant, Transfusion medicine, Coagulopathy, Office of Inspector General, U.S. Department of Health and Human Services, Development, Bleeding, Boston, Temperature, CEO, US Foods, FACEP, Plasma, FDA, Mark (given name), Technology, Spray drying, Pharmaceutical industry

Velico Medical's proprietary spray drying process results in a powdered plasma product that can be stored in a refrigerator or at ambient temperature and then reconstituted on-scene in minutes.

Key Points: 
  • Velico Medical's proprietary spray drying process results in a powdered plasma product that can be stored in a refrigerator or at ambient temperature and then reconstituted on-scene in minutes.
  • Using Velico Medical's spray drying technology and associated products, FrontlineODP will be produced by blood centers around the world.
  • Velico Medical, Inc. is a private US medical technology company, committed to the mission of eliminating preventable death from bleeding.
  • In support of its mission, Velico is developing partnerships with civilian, government and military blood center leadership, trauma surgeons, emergency medical physicians, military medics and first responders worldwide.

Global Antibiotics Markets 2021-2026 by Product Type, Spectrum, Action Mechanism, Geography, Competitive Analysis and the Impact of Covid-19 - ResearchAndMarkets.com

Retrieved on: 
Friday, August 20, 2021
Health, Pharmaceutical, CAGR, BARDA, Vomiting, Growth, Geography, Incidence, Acquisition, Infection, Protein, Government, DNA, Nausea, RNA, Product type, TB, Bayer, Abbott Laboratories, Urinary tract infection, Pneumonia, Cephalosporin, Malaria, USD, Pharmaceutical industry, Antibiotics, Generic drug

The increased incidence of infectious illnesses such as lower respiratory infections, pneumonia, malaria, and TB, among others, are some significant factors driving the growth of the global antibiotics market.

Key Points: 
  • The increased incidence of infectious illnesses such as lower respiratory infections, pneumonia, malaria, and TB, among others, are some significant factors driving the growth of the global antibiotics market.
  • In addition, advancements in antibiotics medicines and innovation and collaboration of the key players are expected to create new opportunities for the global antibiotic market.
  • Furthermore, lack of public knowledge regarding the use of antibiotics is the factor that may create challenges for the growth of the global antibiotic market.
  • The Global Antibiotics Market is segmented further based on Product Type, Spectrum, Action Mechanism, and Geography.

EverGlade Consulting Assists United Safety Technology, Inc. in Securing $97 Million DOD Award

Retrieved on: 
Thursday, August 19, 2021
ACT, Air force, BARDA, Everglade, NIAID, PPE, Department of Defense Office of Inspector General, Technology, United States Department of Health and Human Services, ASPR, Federation, HHS, Pandemic, Assistant, Acquisition, Multimedia, Families First Coronavirus Response Act, UST, CEO, Department of the Air Force Police, DAF, COVID-19, DOD, Department, DTRA, Personal protective equipment, Pharmaceutical industry

WASHINGTON, Aug. 19, 2021 /PRNewswire/ -- EverGlade Consulting ("EverGlade"), a Washington, D.C. based consulting firm, has successfully aided United Safety Technology, Inc. ("UST") in securing $97 million in DOD funding to increase the domestic production capacity of nitrile gloves.

Key Points: 
  • WASHINGTON, Aug. 19, 2021 /PRNewswire/ -- EverGlade Consulting ("EverGlade"), a Washington, D.C. based consulting firm, has successfully aided United Safety Technology, Inc. ("UST") in securing $97 million in DOD funding to increase the domestic production capacity of nitrile gloves.
  • On June 21, 2021, the Department of Defense (DOD), on behalf of and in coordination with the Department of Health and Human Services (HHS), awarded a $96 million award to United Safety Technology, Inc. to increase the domestic production of nitrile gloves.
  • EverGlade Consulting is a Washington, DC based consulting firm that helps clients navigate the federal landscape.
  • For additional information about EverGlade Consulting, visit: https://www.EverGlade.com
    View original content to download multimedia: https://www.prnewswire.com/news-releases/everglade-consulting-assists-un...

Lumen Bioscience Teams with Google to Apply Machine Learning to Biologics Manufacturing

Retrieved on: 
Wednesday, August 11, 2021
NIAID, Bill & Melinda Gates Foundation, United States Army Medical Research and Development Command, Machine learning, AI, National Renewable Energy Laboratory, Temperature, Department, News, Melinda Gates, ACCESS, BARDA, National Institute, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Primary energy, COVID-19, Norovirus, BioRxiv, Infection, U.S. Department of Energy, Office of Inspector General, CHO, National Institute of Allergy and Infectious Diseases, Research, Water, CGMP, PH, Method, Lumen, Rockefeller University, Bill, Photosynthesis, ML, Inflammatory bowel disease, MTEC, Drug development, Protein, Pharmaceutical industry, Fine chemical

The research, led by Caitlin Gamble, Lumen and Drew Bryant at Google Accelerated Science, was funded in part by the Bill & Melinda Gates Foundation.

Key Points: 
  • The research, led by Caitlin Gamble, Lumen and Drew Bryant at Google Accelerated Science, was funded in part by the Bill & Melinda Gates Foundation.
  • Lumen Bioscience simultaneously announced receipt of $2 million in additional grant funding from the Department of Energy to support further development of these research findings.
  • Pending peer-review, the research titled " Machine Learning Optimization of Photosynthetic MicrobeCultivation and Recombinant Protein Production ," has been posted on the online preprint server bioRxiv .
  • Lumen Bioscience discovers, develops, and manufactures biologic drug candidates for several prevalent, worldwide diseasesmany of which currently lack any effective treatments.

Global Custom Antibody Market (2020 to 2028) - COVID-19 Impact and Analysis - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 10, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Other Health, Biotechnology, World Health Organization, Industry, Coronavirus, Therapy, Federation, BARDA, Geography, MEA, CAGR, Antibody, Vaccine, Time, WHO, COVID-19, Research, Economy, Biomedical Advanced Research and Development Authority, Economic security, Severe acute respiratory syndrome coronavirus 2, Investment, Growth, Development, Genome, SCAM, API, Fine chemical, Pharmaceutical industry, Marketing

The "Custom Antibody Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Service, Type, Source, and Research Area, End Users, and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Custom Antibody Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Service, Type, Source, and Research Area, End Users, and Geography" report has been added to ResearchAndMarkets.com's offering.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the custom antibody market.
  • The key findings and recommendations highlight crucial progressive industry trends in the global custom antibody market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results

Retrieved on: 
Tuesday, August 10, 2021
Research, FDA, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, BARDA, Medication, Priority review, CDD, RSE, Patient, FDA, European Medicines Agency, Food, Neurology, RAISE, RPD, COVID-19, Benzodiazepine, Biomedical Advanced Research and Development Authority, Marketing, U.S. Securities and Exchange Commission, Randomness, R, IV, Orion Corporation, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Investment, Leadership, Review, Orion, TSC, Seizure, Oaktree Capital Management, Research, Drug development, GAAP, Therapy, EMA, Epilepsy, Patent, Partnership, Development, NDA, Marinus, General Administration of Sport of China, Johns Hopkins, Security (finance), Johns Hopkins Hospital, Pharmaceutical industry, Cryptocurrency, Animal, Lithium, Ganaxolone, Marinus Pharmaceuticals, GANAXOLONE, MARINUS PHARMACEUTICALS

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today provided an update on its clinical and regulatory development activities and reported its financial results for the second quarter ended June 30, 2021.

Key Points: 
  • (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today provided an update on its clinical and regulatory development activities and reported its financial results for the second quarter ended June 30, 2021.
  • Orions leadership in the European rare orphan disease market and its ability to commercialize both oral and IV ganaxolone makes them a strong partner.
  • 2021 BARDA contract revenues are projected to be in the range of $7 to $10 million for the full year.
  • Total GAAP operating expenses and stock-based compensation estimates remain unchanged from the prior guidance
    Selected Financial Data (in thousands, except share and per share amounts)

US Biologic® and BARDA DRIVe Partner to Develop Oral Flu Vaccines for Home Delivery

Retrieved on: 
Monday, August 9, 2021
Vaccine, Infection, Assistant, COVID-19 contracts in the United Kingdom, University of Tennessee Health Science Center, Drive, Gaps, Needle, Death, University, Partnership, HHS, BARDA, Public health, Biomedical Advanced Research and Development Authority, Influenza vaccine, Doctor of Philosophy, Syringe, Development, CDC, Therapy, Goal

MEMPHIS, Tenn., Aug. 9, 2021 /PRNewswire/ -- US Biologic todayannounces a partnership with BARDA DRIVe to develop oral influenza vaccines, increasing access to these life-saving technologies.

Key Points: 
  • MEMPHIS, Tenn., Aug. 9, 2021 /PRNewswire/ -- US Biologic todayannounces a partnership with BARDA DRIVe to develop oral influenza vaccines, increasing access to these life-saving technologies.
  • "Influenza vaccines should be easily accessible to everyone," says US Biologic CSO, Jolieke G. van Oosterwijk, PhD.
  • US Biologic CEO Mason Kauffman notes "Oral vaccines hold the potential to eliminate the need for needles and syringes, cold-chain logistics, and associated costs.
  • The company's proprietary oral-delivery platform is changing global disease prevention, allowing safe, effective, and cost-efficient delivery of vaccines and therapeutics.